TY - JOUR
T1 - Recent advances in recombinant protein-based malaria vaccines
AU - Draper, Simon J.
AU - Angov, Evelina
AU - Horii, Toshihiro
AU - Miller, Louis H.
AU - Srinivasan, Prakash
AU - Theisen, Michael
AU - Biswas, Sumi
N1 - Funding Information:
SJD is a Jenner Investigator, a Lister Institute Research Prize Fellow and a UK Medical Research Council (MRC) Career Development Fellow [G1000527; this Fellowship is jointly funded by the UK MRC and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement]. EA acknowledges funding from the U.S. Military Infectious Diseases Research Program (MIDRP) and the U.S. Agency for International Development (USAID) through an Interagency Agreement (IAA). TH acknowledges funding from Grant-in-Aid for Scientific Research (A) [grant number 24249024 ] from the Ministry of Education, Culture, Sports, Science and Technology of Japan ; and Global Health Innovative Technology Fund [GHIT RFP 2013-001 ]. LHM and PS are supported by the Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases , National Institutes of Health, USA ; and also acknowledge support from USAID . MT acknowledges funding from the EU FP7 Seventh Framework Program Theme Health-2009-2.3.2-5 [grant 242079 ]; the Danish Council for Strategic research [grant 13127 ]; and the European and Developing Countries Clinical Trials Partnership (EDCTP) [grant I P.2007.3110.001 ]. SB is a NDM Leadership Fellow and Junior Research Fellow of St Catherine's College, Oxford University.
Publisher Copyright:
© 2015 The Authors.
PY - 2015/12/22
Y1 - 2015/12/22
N2 - Plasmodium parasites are the causative agent of human malaria, and the development of a highly effective vaccine against infection, disease and transmission remains a key priority. It is widely established that multiple stages of the parasite's complex lifecycle within the human host and mosquito vector are susceptible to vaccine-induced antibodies. The mainstay approach to antibody induction by subunit vaccination has been the delivery of protein antigen formulated in adjuvant. Extensive efforts have been made in this endeavor with respect to malaria vaccine development, especially with regard to target antigen discovery, protein expression platforms, adjuvant testing, and development of soluble and virus-like particle (VLP) delivery platforms. The breadth of approaches to protein-based vaccines is continuing to expand as innovative new concepts in next-generation subunit design are explored, with the prospects for the development of a highly effective multi-component/multi-stage/multi-antigen formulation seeming ever more likely. This review will focus on recent progress in protein vaccine design, development and/or clinical testing for a number of leading malaria antigens from the sporozoite-, merozoite- and sexual-stages of the parasite's lifecycle-including PfCelTOS, PfMSP1, PfAMA1, PfRH5, PfSERA5, PfGLURP, PfMSP3, Pfs48/45 and Pfs25. Future prospects and challenges for the development, production, human delivery and assessment of protein-based malaria vaccines are discussed.
AB - Plasmodium parasites are the causative agent of human malaria, and the development of a highly effective vaccine against infection, disease and transmission remains a key priority. It is widely established that multiple stages of the parasite's complex lifecycle within the human host and mosquito vector are susceptible to vaccine-induced antibodies. The mainstay approach to antibody induction by subunit vaccination has been the delivery of protein antigen formulated in adjuvant. Extensive efforts have been made in this endeavor with respect to malaria vaccine development, especially with regard to target antigen discovery, protein expression platforms, adjuvant testing, and development of soluble and virus-like particle (VLP) delivery platforms. The breadth of approaches to protein-based vaccines is continuing to expand as innovative new concepts in next-generation subunit design are explored, with the prospects for the development of a highly effective multi-component/multi-stage/multi-antigen formulation seeming ever more likely. This review will focus on recent progress in protein vaccine design, development and/or clinical testing for a number of leading malaria antigens from the sporozoite-, merozoite- and sexual-stages of the parasite's lifecycle-including PfCelTOS, PfMSP1, PfAMA1, PfRH5, PfSERA5, PfGLURP, PfMSP3, Pfs48/45 and Pfs25. Future prospects and challenges for the development, production, human delivery and assessment of protein-based malaria vaccines are discussed.
KW - Adjuvant
KW - Antibody
KW - Malaria
KW - Plasmodium falciparum
KW - Recombinant protein
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=84950997226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84950997226&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2015.09.093
DO - 10.1016/j.vaccine.2015.09.093
M3 - Article
C2 - 26458807
AN - SCOPUS:84950997226
SN - 0264-410X
VL - 33
SP - 7433
EP - 7443
JO - Vaccine
JF - Vaccine
IS - 52
ER -